Posts tagged beta-amyloid
Leerink starts AC Immune at outperform

Leerink initiated coverage of AC Immune SA (NASDAQ:ACIU) with an “outperform” rating and $22 price target. The stock closed at $14.43 on Friday.

AC Immune is focused on developing novel medicines for neurodegenerative disorders. Its lead asset, crenezumab, which is partnered with Roche/Genentech, is a monoclonal antibody that binds multiple sub-types of beta-amyloid.

Read More